Anipryl (selegiline; 1-deprenyl)?
draxis.com
I once owned shares in Deprenyl Research Ltd. / Deprenyl Animal Health Inc.
DEPLF('87)/DAHI('91)--->Draxis(renamed '94)/DAHI---+Pfizer(rights).
The original target for deprenyl was the treatment of Parkinson's in humans. The former Chairman of the company, Dr. Morton Shulman, had that disease. It is sold under the brand name Eldepryl by Draxis and others. They get the 1-deprenyl from the Hungarian company Chinoin that developed it. Some also believe the drug has potential to increase life expectancy. They later extended the patient pool from people and lab rats to include household pets. I believe it's basically the same stuff. The DAHI IPO was in 1991, so it took ~7 years for approval, much longer than they expected.
This is from the 1996 Form 20-F on Draxis' website:
Canadian Pharmaceutical Unit / Products Being Marketed
Eldepryl® is a selective monoanimine oxidase-type B ("MAO-B") inhibitor and is used in the treatment of Parkinson's disease. MAO-B is an enzyme that degrades the structure of certain compounds, such as dopamine, which regulate various physiological functions, including certain aspects of central nervous system activity. Dopamine is a neurotransmitter which facilitates movement, posture, balance and walking. Eldepryl® has several common or generic names, including selegiline hydrochloride, selegiline and l-deprenyl. In addition to being marketed by the Company in Canada, Eldepryl® is marketed by others in Switzerland, Sweden, France, Finland, Germany, Hungary, Italy, the United Kingdom, and the United States and other countries for the treatment of Parkinson's disease. Eldepryl® is also marketed in Italy for the treatment of Alzheimer's disease.
The Somerset division of Mylan Labs also sells it. Product labeling:
eldepryl.com
Bonus: Fido's protected against the 'cheese reaction'! |
